ViroPharma acquires option to acquire Meritage; Shire later exercises option for up to $245mm
Executive Summary
Rare disease drug developer ViroPharma Inc. has received the exclusive option to acquire privately held GI-focused Meritage Pharma Inc. in exchange for $7.5mm up front, plus up to $12.5mm in option milestones based on the attainment of certain clinical development and regulatory goals.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice